|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/20 Genethera Inc 10-Q 9/30/19 37:1.6M Highland Services/FA |
Document/Exhibit Description Pages Size
1: 10-Q Genethera, Inc. 09/30/2019 10-Q HTML 207K
2: EX-31.1 Certificate of the Chief Executive Officer HTML 21K
Pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002
3: EX-31.2 Certificate of the Chief Financial Officer HTML 21K
Pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002
4: EX-32.1 Certificate of the Chief Executive Officer HTML 14K
Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002
5: EX-32.2 Certificate of the Chief Financial Officer HTML 14K
Pursuant to 18 U.S.C. Section 1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002
27: R1 Document and Entity Information HTML 47K
17: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 95K
20: R3 Condensed Consolidated Balance Sheets (Unaudited) HTML 36K
(Parenthetical)
37: R4 Condensed Consolidated Statements of Operations HTML 58K
(Unaudited)
28: R5 Condensed Consolidated Statements of Stockholders' HTML 40K
(Deficit) (Unaudited)
18: R6 Condensed Consolidated Statements of Cash Flows HTML 84K
(Unaudited)
21: R7 Organization and nature of operations and summary HTML 55K
of significant accounting policies
36: R8 Going Concern HTML 18K
29: R9 Property and Equipment HTML 17K
14: R10 Related party transactions HTML 21K
23: R11 Accrued expenses HTML 19K
34: R12 Convertible notes payable HTML 21K
31: R13 Shareholders' equity HTML 20K
13: R14 Commitments HTML 25K
22: R15 Subsequent events HTML 17K
33: R16 Organization and nature of operations and summary HTML 108K
of significant accounting policies (Policy)
30: R17 Accrued expenses (Tables) HTML 19K
12: R18 Organization and nature of operations and summary HTML 18K
of significant accounting policies (Details
Narrative)
24: R19 Going Concern (Details Narrative) HTML 19K
35: R20 Property and Equipment (Details Narrative) HTML 18K
26: R21 Related party transactions (Details Narrative) HTML 35K
15: R22 Accrued expenses (Details) HTML 26K
19: R23 Shareholders' equity (Details Narrative) HTML 40K
25: XML IDEA XML File -- Filing Summary XML 57K
16: EXCEL IDEA Workbook of Financial Reports XLSX 32K
6: EX-101.INS XBRL Instance -- gnth-20190930 XML 394K
8: EX-101.CAL XBRL Calculations -- gnth-20190930_cal XML 83K
9: EX-101.DEF XBRL Definitions -- gnth-20190930_def XML 153K
10: EX-101.LAB XBRL Labels -- gnth-20190930_lab XML 341K
11: EX-101.PRE XBRL Presentations -- gnth-20190930_pre XML 269K
7: EX-101.SCH XBRL Schema -- gnth-20190930 XSD 58K
32: ZIP XBRL Zipped Folder -- 0001199835-20-000098-xbrl Zip 49K
EXHIBIT 31.1
CERTIFICATION
OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Antonio Milici, certify that:
| 1. | I have reviewed this Form 10-Q for the fiscal quarter ended September 30, 2019 of GeneThera, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: March 30, 2020
| /s/ Antonio Milici | |
| Antonio Milici | |
| President and Chief Executive Officer | |
| (Principal Executive Officer) | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 3/31/20 | 10-Q, 10-Q/A | ||
| Filed on: | 3/30/20 | 10-Q, NT 10-K | ||
| For Period end: | 9/30/19 | |||
| List all Filings | ||||